Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial.

Authors

Alison Backen

Alison Catherine Backen

University of Manchester (Institute of Cancer Sciences), Manchester, United Kingdom

Alison Catherine Backen , Mairead G McNamara , Andre Lopes , Harpreet Wasan , Daniel H. Palmer , Marian Duggan , David Cunningham , Alan Anthoney , Philippa Corrie , Srinivasan Madhusudan , Anthony Maraveyas , Paul J. Ross , Justin S. Waters , William P. Steward , Charlotte Rees , Sandy Beare , John A. Bridgewater , Caroline Dive , Juan W. Valle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT00939848

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4085)

DOI

10.1200/jco.2015.33.15_suppl.4085

Abstract #

4085

Poster Bd #

195

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

A phase II study of ramucirumab for advanced, pre-treated biliary cancers.

A phase II study of ramucirumab for advanced, pre-treated biliary cancers.

First Author: Jonathan Mizrahi

Poster

2019 ASCO Annual Meeting

Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).

Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).

First Author: Dae Won Kim